Second consensus on medical treatment of metastatic breast cancer

被引：80

作者：

Beslija, S. ^{[1
]}

Bonneterre, J. ^{[1
]}

Burstein, H. ^{[1
]}

Cocquyt, V. ^{[1
]}

Gnant, M. ^{[1
]}

Goodwin, P. ^{[1
]}

Heinemann, V. ^{[1
]}

Jassem, J. ^{[1
]}

Koestler, W. J. ^{[1
]}

Krainer, M. ^{[1
]}

Menard, S. ^{[1
]}

Petit, T. ^{[1
]}

Petruzelka, L. ^{[1
]}

Possinger, K. ^{[1
]}

Schmid, P. ^{[1
]}

Stadtmauer, E. ^{[1
]}

Stockler, M. ^{[1
]}

Van Belle, S. ^{[1
]}

Vogel, C. ^{[1
]}

Wilcken, N. ^{[1
]}

Wiltschke, C. ^{[1
]}

Zielinski, C. C. ^{[1
]}

Zwierzina, H. ^{[1
]}

机构：

[1] CECOG, A-1090 Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2007年 / 18卷 / 02期

关键词：

chemotherapy; endocrine therapy; medical treatment; metastatic breast cancer; targeted therapy;

D O I：

10.1093/annonc/mdl155

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.

引用

页码：215 / 225

页数：11

共 101 条

[1]

Albain KS, 2004, J CLIN ONCOL, V22, p5S

[2] Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule [J].

Baselga, J ;

Carbonell, X ;

Castañeda-Soto, NJ ;

Clemens, M ;

Green, M ;

Harvey, V ;

Morales, S ;

Barton, C ;

Ghahramani, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2162-2171

[3] Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines [J].

Bennett, CL ;

Weeks, JA ;

Somerfield, MR ;

Feinglass, J ;

Smith, TJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3676-3681

[4]

BERTELLI G, 2002, P AN M AM SOC CLIN, V21, pA60

[5]

Beslija S, 2003, BREAST CANCER RES TR, V81, pS1

[6] Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial [J].

Biganzoli, L ;

Cufer, T ;

Bruning, P ;

Coleman, R ;

Duchateau, L ;

Calvert, AH ;

Gamucci, T ;

Twelves, C ;

Fargeot, P ;

Epelbaum, R ;

Lohrisch, C ;

Piccart, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3114-3121

[7] INFLUENCE OF TREATMENT SCHEDULE ON TOXICITY AND EFFICACY OF CYCLOPHOSPHAMIDE, EPIRUBICIN, AND FLUOROURACIL IN METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL COMPARING WEEKLY AND EVERY-4-WEEK ADMINISTRATION [J].

BLOMQVIST, C ;

ELOMAA, I ;

RISSANEN, P ;

HIETANEN, P ;

NEVASAARI, K ;

HELLE, L .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :467-473

[8] OVARIAN ABLATION VERSUS GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PRE-PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - RESULTS OF A MULTICENTRIC ITALIAN STUDY [J].

BOCCARDO, F ;

RUBAGOTTI, A ;

PERROTTA, A ;

AMOROSO, D ;

BALESTRERO, M ;

DEMATTEIS, A ;

ZOLA, P ;

SISMONDI, P ;

FRANCINI, G ;

PETRIOLI, R ;

SASSI, M ;

PACINI, P ;

GALLIGIONI, E .

ANNALS OF ONCOLOGY, 1994, 5 (04) :337-342

[9] Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer [J].

Bonneterre, J ;

Dieras, V ;

Tubiana-Hulin, M ;

Bougnoux, P ;

Bonneterre, ME ;

Delozier, T ;

Mayer, F ;

Culine, S ;

Dohoulou, N ;

Bendahmane, B .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1466-1471

[10] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study [J].

Bonneterre, J ;

Thürlimann, B ;

Robertson, JFR ;

Krzakowski, M ;

Mauriac, L ;

Koralewski, P ;

Vergote, I ;

Webster, A ;

Steinberg, M ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3748-3757

← 1 2 3 4 5 6 7 8 9 10 →